ReviewMetabolic brain disease2026
Epitranscriptomic and immunometabolic mechanisms of traditional Chinese medicine in metabolic-associated cognitive impairment: a narrative review.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Metabolic-associated cognitive impairment (MACI) is a major complication of metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD). It manifests as impairments in learning, memory, and executive function, with pathogenesis involving insulin resistance, chronic low-grade inflammation, immune–metabolic imbalance, synaptic plasticity deficits, and aberrant epitranscriptomic regulation. In recent years, traditional Chinese medicine (TCM), with its multi-component and multi-target characteristics, has demonstrated unique advantages in preventing and treating MACI. Emerging evidence indicates that TCM can modulate RNA modifications (e.g., m6A), improve immune–metabolic homeostasis, suppress neuroinflammation, and restore synaptic plasticity to enhance cognitive function. This review summarizes the pathological mechanisms of MACI, highlights recent advances in understanding how TCM exerts therapeutic effects through epitranscriptomic and immunometabolic pathways, and discusses the application of network pharmacology, multi-omics, and spatial transcriptomics in elucidating TCM mechanisms. Finally, we address challenges and future directions for the clinical translation of TCM, emphasizing that integration of multi-omics approaches and precision medicine strategies may facilitate innovative applications of TCM in MACI management.
Indexed as
Identifiers
41941040What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.